Literature DB >> 21397740

Changes in chemical composition of cortical bone associated with bone fragility in rat model with chronic kidney disease.

Yoshiko Iwasaki1, Junichiro James Kazama, Hideyuki Yamato, Masafumi Fukagawa.   

Abstract

Bone fragility is a complication of chronic kidney disease (CKD). Patients on dialysis have higher risk of fracture than the general population, but the reason remains obscure. Bone strength is determined by bone mass and bone quality. Although factors affecting bone quality include microarchitecture, remodeling activity, mineral content, and collagen composition, it remains unclear which factor is critically important for bone strength in CKD. We conducted an in vivo study to elucidate the factors that reduce bone mechanical property in CKD. Rats underwent thyroparathyroidectomy and progressive partial nephrectomy (TPTx-Nx). Bone mechanical property, bone mineral density (BMD), and cortical bone chemical composition (all in femur) as well as histomorphometry (in tibia) were determined. The storage modulus, which is a mechanical factor, was reduced in CKD model rats compared with controls that underwent thyroparathyroidectomy alone (TPTx). There were no differences in BMD and histomorphometric parameters between groups. However, cortical bone chemical composition differed: mineral to matrix ratio and carbonate substitution increased whereas crystallinity decreased in TPTx-Nx. In addition, enzymatic crosslinks ratio and pentosidine to matrix ratio also increased. These changes were significant in TPTx-Nx rats with most impaired renal function. Stepwise multiple regression analysis identified mature to immature crosslink ratio and crystallinity as independent contributors to storage modulus. Deteriorated bone mechanical properties in CKD may be caused by changes in chemical composition of the cortical bone, and is independent of BMD or cancellous bone microarchitecture.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21397740     DOI: 10.1016/j.bone.2011.03.672

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  33 in total

Review 1.  Contributions of Raman spectroscopy to the understanding of bone strength.

Authors:  Gurjit S Mandair; Michael D Morris
Journal:  Bonekey Rep       Date:  2015-01-07

Review 2.  Vibrational spectroscopic techniques to assess bone quality.

Authors:  E P Paschalis; S Gamsjaeger; K Klaushofer
Journal:  Osteoporos Int       Date:  2017-04-05       Impact factor: 4.507

3.  Alendronate does not prevent long bone fragility in an inactive rat model.

Authors:  K Naruse; K Uchida; M Suto; K Miyagawa; A Kawata; K Urabe; M Takaso; M Itoman; Y Mikuni-Takagaki
Journal:  J Bone Miner Metab       Date:  2015-10-16       Impact factor: 2.626

Review 4.  Bone composition: relationship to bone fragility and antiosteoporotic drug effects.

Authors:  Adele L Boskey
Journal:  Bonekey Rep       Date:  2013-12-04

5.  PTH signaling mediates perilacunar remodeling during exercise.

Authors:  Joseph D Gardinier; Salam Al-Omaishi; Michael D Morris; David H Kohn
Journal:  Matrix Biol       Date:  2016-02-23       Impact factor: 11.583

6.  Effects of raloxifene and alendronate on non-enzymatic collagen cross-links and bone strength in ovariectomized rabbits in sequential treatments after daily human parathyroid hormone (1-34) administration.

Authors:  S Kimura; M Saito; Y Kida; A Seki; Y Isaka; K Marumo
Journal:  Osteoporos Int       Date:  2016-10-29       Impact factor: 4.507

7.  Compromised vertebral structural and mechanical properties associated with progressive kidney disease and the effects of traditional pharmacological interventions.

Authors:  Christopher L Newman; Neal X Chen; Eric Smith; Mark Smith; Drew Brown; Sharon M Moe; Matthew R Allen
Journal:  Bone       Date:  2015-04-17       Impact factor: 4.398

8.  Moderate chronic kidney disease impairs bone quality in C57Bl/6J mice.

Authors:  Chelsea M Heveran; Alicia M Ortega; Andrew Cureton; Ryan Clark; Eric W Livingston; Ted A Bateman; Moshe Levi; Karen B King; Virginia L Ferguson
Journal:  Bone       Date:  2016-02-06       Impact factor: 4.398

9.  Skeletal effects of zoledronic acid in an animal model of chronic kidney disease.

Authors:  M R Allen; N X Chen; V H Gattone; X Chen; A J Carr; P LeBlanc; D Brown; S M Moe
Journal:  Osteoporos Int       Date:  2012-08-21       Impact factor: 4.507

10.  Evaluation of the toxic effect of the herbicide 2, 4-D on rat hepatocytes: an FT-IR spectroscopic study.

Authors:  Tahani H Dakhakhni; Gehan A Raouf; Safaa Y Qusti
Journal:  Eur Biophys J       Date:  2015-12-02       Impact factor: 1.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.